Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P450 3A4

Published 2021 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Infigratinib is a Reversible Inhibitor and Mechanism-based Inactivator of Cytochrome P450 3A4
Authors
Keywords
-
Journal
DRUG METABOLISM AND DISPOSITION
Volume -, Issue -, Pages DMD-AR-2021-000508
Publisher
American Society for Pharmacology & Experimental Therapeutics (ASPET)
Online
2021-07-30
DOI
10.1124/dmd.121.000508

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Create your own webinar

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.